AI assistant
Sending…
Allogene Therapeutics, Inc. — Director's Dealing 2021
Jun 11, 2021
33378_dirs_2021-06-11_c1dadc6a-3725-43fa-bbad-2066d7dc3746.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-06-10
Reporting Person: MESSEMER DEBORAH M. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-10 | Stock Option (Right to Buy) | $25.76 | A | 28015 | Acquired | 2031-06-10 | Common Stock (28015) | Direct |
Footnotes
F1: The stock option vests in 12 equal monthly installments beginning July 10, 2021.
More from Allogene Therapeutics, Inc.
Proxy Solicitation & Information Statement
2026
May 28
Regulatory Filings
2026
May 28
Proxy Solicitation & Information Statement
2026
May 20
Regulatory Filings
2026
May 13
Regulatory Filings
2026
Apr 15
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 13
Director's Dealing
2026
Mar 4
Major Shareholding Notification
2026
Feb 17